From Yahoo Finance: 2025-05-11 09:00:00

Experts predict a recession in 2025, impacting the stock market. J.P. Morgan cites a 60% chance due to trade wars. AbbVie, a strong stock, thrives in downturns. The company diversified away from Humira and shows growth potential. Investors seek safety and dividends in AbbVie amid market uncertainty.

AbbVie’s strategic acquisitions have boosted revenue, with Skyrizi and Rinvoq sales soaring. The company’s earnings in Q1 2025 exceeded expectations, with a raised sales guidance for the year. AbbVie’s steady growth and dividend yield make it an attractive option during economic challenges. Analysts maintain a bullish outlook on the stock.

While AbbVie isn’t a fast-growing stock, it offers stability and income. The Motley Fool highlights 10 other stocks for potential high returns. AbbVie’s long-term growth and dividend track record make it a solid choice for weathering market storms. The company’s resilience and strategic acquisitions position it well for the future.

Read more: Recession Worries? Here’s 1 of the Best Dividend Stocks for Turbulent Times